Abstract. Epithelial cell transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor and its expression is associated with the development of malignant tumor types. However, to the best of our knowledge, there is no information on the role of ECT2 in the development and progression of laryngeal squamous cell carcinoma (LSCC). The present study aimed at investigating the expression pattern and potential role of ECT2 in the development and progression of LSCC. The expression of ECT2 in 81 pairs of LSCC and adjacent non-tumor tissues was characterized by immunohistochemistry and reverse transcription-quantitative polymerase chain reaction. ECT2 expression was upregulated in LSCC tissues and associated significantly with poor differentiation, higher stages, lymph node metastasis and poor survival in the sample population. The relative expression levels of ECT2 mRNA transcripts were correlated with the intensity of anti-ECT2 staining in 25 ECT2+LSCC specimens selected randomly. These results indicated that ECT2 expression was crucial for the progression of LSCC and may serve as a biomarker for the diagnosis and prognosis of LSCC.
Introduction
Laryngeal cancer is one of the most common malignancies in the respiratory system globally (1) , and the number of new cases of laryngeal cancer has reached 3.0 per 100,000 people annually between 2011 and 2015 due to excessive tobacco and alcohol consumption (2) (3) (4) . Furthermore, exposure to asbestos, dust and polycyclic aromatic hydrocarbons is associated with an increased risk of laryngeal squamous cell carcinoma (LSCC) development (3, 5, 6) . Despite the fact that therapeutic strategies, including surgical techniques, chemotherapeutic drugs and radiotherapy, have advanced, the 5-year overall survival rate of patients with LSCC remains as low as 61% (7) . The pathogenesis of LSCC remains unclear and understanding the factors contributing to the development and progression is crucial for the discovery of novel therapeutic targets, in addition to the management of patients with LSCC.
Epithelial cell transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor and can regulate the process of cell cycling and cytokinesis (8) . ECT2 contains two BRCA1 C Terminus (BRCT) domains within the N-terminus, including a DBL-homology domain and a pleckstrin homology domain (9) . Previous studies reported that ECT2 is localized in the actin cortex and central spindles, as ECT2 is crucial for the cleavage furrow formation during cytokinesis (10, 11) . The upregulated ECT2 expression and its misplacement have been indicated to be associated with the tumorigenesis and the development of numerous malignant tumors, including lung cancer, ovarian cancer and primary brain cancer (12) (13) (14) , in addition to poor survival in patients with colorectal cancer or lung adenocarcinoma (15, 16) . However, to the best of our knowledge, there is no information on the levels of ECT2 expression and its role in the development and progression of LSCC.
In the present study, ECT2 expression was analyzed in 81 LSCC specimens and adjacent non-tumor tissues, and the association between the levels of ECT2 expression and clinical characteristics of patients with LSCC was examined. RT-qPCR. Total RNA was extracted from individual tissue samples with TRIzol ® (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer's protocols, and the RNA (1 µg per sample) was reversely transcribed into cDNA using a PrimeScript™ RT-PCR kit (Takara Bio, Inc., Otsu, Japan), according to the manufacturer's protocols. The relative expression levels of ECT2 to the control GAPDH mRNA transcripts were determined by RT-qPCR using a SYBR™ Green PCR Master mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) and specific primers. The sequences of the primers were as follows: ECT2 (119 bp) forward, 5'-GCCATAATGCTTTTGCCTTGCTTG-3' and reverse 5'-TCGACACAGCATCTTTAGCCAGTTT-3'; GAPDH (177 bp) forward, 5'-GGGCCAAAAGGGTCATCA TCTC-3'and reverse 5'-GCCCTTCCACGATGCCAAA-3'. The PCR reactions were performed in triplicate and the thermocycling conditions were as follows: 95˚C for 5 min; and 40 cycles of 95˚C for 30 sec, 57˚C for 30 sec and 72˚C for 30 sec. The data were analyzed by the 2 -ΔΔCq method (18) .
Patients and methods

LSCC
Immunohistochemistry. The tissues were fixed in 10% neutral buffered formalin for 24 h at room temperature and then dehydrated in an ascending ethanol series and cleared with 3 changes of xylene, followed by paraffin-embedding. The paraffin-embedded tissue sections (thickness, 4 µm) were de-paraffinized, rehydrated in a descending ethanol series and treated with 0.3% H 2 O 2 . The sections were heated in 1% citrate buffer for 5 min at 90-100˚C for antigen retrieval, and blocked with 10% normal goat serum (Gemini Bio-Products, Sacramento, CA, USA) for 1 h at room temperature. Subsequent to being washed, the sections were incubated with rabbit anti-ECT2 antibodies (cat. no. bs-4102R; 1:50 dilution; BIOSS, Beijing, China) (19, 20) overnight at 4˚C. The negative control sections were incubated with PBS. After being washed three times with PBST, the bound antibodies were detected with horseradish peroxidase-conjugated anti-IgG (cat. no. 111-035-144; 1:5,000 dilution; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) and immunoreactive signals were developed using diaminobenzidine tetrachloride, followed by counterstaining with haematoxylin for 2 min at room temperature. The staining was observed in a light microscope (x200, magnification). 
Results
ECT2 expression was upregulated in LSCC tissues and correlated with poor differentiation of LSCC.
To determine the potential role of ECT2 in the development and progression of LSCC, 81 patients with LSCC were recruited and their demographic and clinical characteristics are presented in Table I . The expression levels of ECT2 expression were examined by immunohistochemistry. As indicated in Fig. 1 , ECT2 protein was primarily expressed in the cytoplasm of tumor cells. A limited expression of ECT2 was detected in the matched adjacent non-tumor tissues, while an upregulated ECT2 protein expression was detected in LSCC, particularly in the low differentiated tumor tissues (P=0.039). Stratification analysis indicated that the increased levels of ECT2 expression were significantly associated with the medium and low differentiation of LSCC (P=0.039; Table I), increased TNM stages (P= 0.016), increased overall stages (P= 0.007) and lymph node metastasis (P=0.04); however, it was not significantly associated with sex, age, primary tumor site and smoking status in this population (Table I) .
To further validate the data, the expression levels of ECT2 mRNA transcripts were determined in 25 pairs of LSCC and matched non-tumor tissue samples by RT-qPCR. The relative expression levels of ECT2 mRNA transcripts in the LSCC tissues were significantly increased, compared with the matched adjacent non-tumor tissues (P<0.01; Fig. 2A) . The relative expression levels of ECT2 mRNA transcripts in 25 LSCC were positively correlated with the intensity of anti-ECT2 staining (R= 0.938; P<0.05; Fig. 2B ). Therefore, increased levels of ECT2 expression are associated with lower differentiation of LSCC and may contribute to the development and progression of poorly differentiated LSCC.
ECT2 expression was negatively correlated with overall survival time of LSCC patients.
A total of 81 patients with LSCC were followed-up. Among them, seven cases (8.4%) Table I . Association of ECT2 expression with clinicopathological characteristics of patients with LSCC. were lost for follow-up, due to personal reasons. Stratification analysis indicated that the overall survival time period of patients with increased ECT2 expressing LSCC was significantly reduced, compared with those with reduced ECT2 expressing LSCC (P=0.046; Fig. 2C ). Therefore, increased levels of ECT2 are associated with poor prognosis of LSCC.
ECT2 expression -----------------------------------------------------------------------------
Discussion
LSCC invasion and metastasis are leading causes of mortality (22) . However, to the best of our knowledge, no reliable prognostic biomarkers for LSCC have been identified. ECT2 is physiologically expressed primarily in the nucleus and spreads into the cytoplasm of cells during mitosis (13) . ECT2 can be misplaced in the cytoplasm, where ECT2 binds to the protein kinase Cι/polarity protein 6α (PKCι/Par6α) complex and is phosphorylated by PKCι to activate Rac family small GTPase 1 (Rac1), and promote the proliferation and invasion of non-small cell lung carcinoma (NSCLC) cells (23) . Furthermore, PKCι or Par6α silencing also promotes the redistribution of ECT2 from the cytoplasm to nucleus (24) . Therefore, PKCι/Par6α complex in NSCLC regulates ECT2 cytoplasmic retention to induce phosphorylation and activation of downstream Rac1, conferring its oncogenic activity (24) . In the present study, it was indicated that the upregulated ECT2 expression was primarily located in the cytoplasm of LSCC. This indicated that upregulated ECT2 expression in the cytoplasm may contribute to the development and progression of LSCC through similar mechanisms.
In the present study, it was indicated that upregulated ECT2 expression was associated with reduced differentiation, increased TNM stage, and lymph node metastasis of LSCC in the sample population. It has been reported that lowly differentiated tumors are associated with aggressive progression and poor prognosis in numerous malignant tumor types, including epithelial ovarian carcinoma, bladder squamous cell carcinoma and thyroid carcinoma (25) (26) (27) (28) . Because up-regulation of ECT2 and its misplacement are demonstrated in lowly differentiated LSCC, ECT2 may serve as a potential biomarker for the prognosis of LSCC.
Increased levels of ECT2 expression were associated significantly with poor overall survival time period of patients with LSCC. The data of the present study is in accordance to previous reports on other malignant tumors including lung cancer, colorectal cancer, and ovarian cancer (15, 16, 29, 30) and indicate that ECT2 may serve as an oncogenic factor to promote the progression of LSCC. Therefore, an increased ECT2 expression is a valuable biomarker for differentially diagnosis and prognosis of LSCC.
There are a number of limitations in the present study, including small sample size. Therefore, larger sample sizes are required in order to examine the potential molecular mechanisms underlying the action of ECT2 in promoting the progression of LSCC.
